StreetInsider.com News Articles

Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss

Tue, 29 Sep 2026 08:32:37 -0400

Propanc Biopharma, Inc. (NASDAQ: PPCB) reported a net loss of $18.9 million for the fiscal year ended June 30, 2026, and said it plans to begin a Phase 1b first-in-human clinical study of its lead drug candidate, PRP, in the first quarter of 2027, according to a company press release.

The Melbourne, Australia-based biopharmaceutical company said the multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial sites across Australia. The study includes a dose escalation phase followed by a dose expansion phase.

Total assets stood at $12.78 million as

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Tue, 29 Sep 2026 08:30:00 -0400

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia.

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Tue, 29 Sep 2026 08:30:00 -0400

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia.

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Tue, 29 Sep 2026 08:30:00 -0400

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors,

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Tue, 29 Sep 2026 08:30:00 -0400

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors,

Form 10-K Propanc Biopharma, Inc. For: Jun 30

Fri, 25 Sep 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260925/27108152.html

Propanc releases preclinical PDAC data for PRP, eyes 2027 trial

Tue, 22 Sep 2026 08:31:21 -0400

Propanc Biopharma (Nasdaq: PPCB) released a comparative analysis of its lead drug candidate PRP against clinical data from Erasca's pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma (PDAC), according to a company statement.

In orthotopic and patient-derived xenograft preclinical models of advanced PDAC, PRP — a fixed-ratio combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen — achieved greater than 90% mean tumor-growth inhibition versus vehicle controls and a median overall survival extension of more than 2.5-fold compared with controls. The preclinical data also showed reduced metastatic burden in the liver and peritoneum, tumor microenvironment remodeling, and enhanced sensitivity of chemo-resistant PDAC

Propanc releases preclinical PDAC data for PRP, eyes 2027 trial

Tue, 22 Sep 2026 08:31:21 -0400

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Tue, 22 Sep 2026 08:30:00 -0400

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset

MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca, Inc.’s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma (PDAC).

The analysis follows FDA approval of Revolution Medicines’ daraxonrasib

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Tue, 22 Sep 2026 08:30:00 -0400

The analysis follows FDA approval of Revolution Medicines’ daraxonrasib

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Wed, 16 Sep 2026 08:30:00 -0400

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS Therapies

MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of its lead candidate PRP against recently reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines’ daraxonrasib (RASONQUE™; RMC-6236) and Erasca’s pan-RAS molecular glue ERAS-0015.

The analysis is

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Wed, 16 Sep 2026 08:30:00 -0400

The analysis is

Propanc Biopharma plans Phase 1b cancer drug trial for February 2027

Wed, 09 Sep 2026 08:30:38 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced plans to begin a Phase 1b first-in-human study of its drug candidate PRP in February 2027, according to a company press release.

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial sites across Australia. The study is designed in two parts: a dose-escalation phase followed by a dose-expansion phase, intended to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of PRP.

PRP will be administered as a weekly intravenous infusion on days 1, 8, 15, and 22 of each 28-day cycle.

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Wed, 09 Sep 2026 08:30:00 -0400

Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia

MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027.

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Wed, 09 Sep 2026 08:30:00 -0400

Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia

Propanc reports preclinical pancreatic cancer data for PRP drug candidate

Thu, 27 Aug 2026 08:30:44 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced preclinical data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP produced greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001), a median overall survival extension of more than 2.5-fold in treated animals compared with controls, and a reduction in metastatic burden in the liver and peritoneum.

The data also showed remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity and reduced fibrosis, as well as enhanced sensitivity of chemo-resistant PDAC

Propanc reports preclinical pancreatic cancer data for PRP drug candidate

Thu, 27 Aug 2026 08:30:44 -0400

Propanc Biopharma, Inc. (Nasdaq: PPCB) announced preclinical data for its lead drug candidate PRP in pancreatic ductal adenocarcinoma (PDAC), according to a company press release.

The data also showed remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity and reduced fibrosis, as well as enhanced sensitivity of chemo-resistant PDAC

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Thu, 27 Aug 2026 08:30:00 -0400

MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC).